Introduction
Urinary incontinence is a devastating medical and social condition that is increasing in the United States due to an aging population. Presently, the estimated annual cost of caring for affected persons is over $16 billion, with the greatest portion being spent on management measures, such as adult diapers and pads, rather than on treatment. 1 One type of urinary incontinence, stress incontinence, is due to sphincter deficiency, while another more common and serious type, overflow incontinence, is due to impaired detrusor contractility. 1 This is an increasingly common condition in the geriatric population and in patients with neurological diseases, especially diabetes mellitus. [2] [3] [4] Due to inadequate contractility, the bladder cannot empty its urine content, which not only leads to incontinence, but also to urinary tract infections and even renal insufficiency. With no effective medication currently available, clinicians are limited in their ability to treat impaired detrusor contractility. 5, 6 Current treatments for urinary incontinence caused by urethral or bladder dysfunction include surgical repair or the injection of bulking agents. The injection of bulking agents is less invasive than surgery and achieves good short-term results for relieving urinary incontinence. However, the overall success of this procedure is hindered by the reabsorption of collagen, the need for multiple injections, and the allergic reaction caused by foreign substances in some patients, all of which limit its overall success. We are exploring a new treatment for bladder dysfunction by using gene therapy and tissue engineering based on a novel population of musclederived cells that display stem cell characteristics.
Over the last few years, muscle-based tissue engineering and cell transplantation have become attractive methods for the treatment of many conditions of the musculoskeletal system. [7] [8] [9] [10] However, the transplantation of donor muscle cells into host muscle has been hindered by various limitations, such as immune rejection that consequently leads to poor spreading and survival of injected cells. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The success of cell transplantation may be dramatically improved by using a specific population of cells that has the capacity to overcome these hurdles.
Indeed, we have recently isolated highly purified MDC that have displayed dramatically improved cell survival after transplantation when injected intramuscularly. 20 These cells were harvested from a muscle biopsy and purified by the preplate technique based on their adherence characteristics to collagen-coated flasks. [20] [21] [22] The purified MDC (pp6) used for these experiments took about 6 days to adhere to collagen-coated flasks and stained positive for myogenic (desmin) and well-known stem cell markers, including Sca-1 and FLK-1. 9 These results suggest that this population of highly purified MDC may contain stem cells.
It has been reported by another research group that a small population of MDC that can survive after implantation may represent a type of myogenic stem cell. 23 It is now well established that muscle satellite cells are heterogenous and that skeletal muscle tissue may be a source for pluripotent stem cells. 7, 9, [24] [25] [26] [27] [28] [29] In particular, stem cell populations from muscle were recently shown to reconstitute the hematopoietic compartment of lethally irradiated mice and to partially restore the expression of dystrophin in the mdx mouse, an animal model of Duchenne muscular dystrophy. 7 In our laboratory, we have shown that the population of MDC (pp6) was, in fact, multipotent and had the capability of differentiating into other mesenchymal tissues, such as osteogenic lineage. 9 We have reported that mc13 cells, a clonal population of muscle-derived stem cells isolated from these highly purified myogenic cells (pp6), demonstrated the capacity to differentiate into myogenic, as well as osteogenic lineages both in vitro and in vivo. 9 These results suggest that mc13 cells possess stem cell-like characteristics and are able to differentiate into multiple lineages. Therefore, in this project we have investigated whether MDC (pp6 and mc13) can differentiate into both myofibers that become innervated by the host bladder tissue and into the smooth muscle lineage, which consequently leads to the improvement of bladder function.
These experiments were designed to test the feasibility of muscle-based gene therapy and tissue engineering in the domain of urological dysfunction and to explore the potential use of these purified pp6, as well as mc13, as alternative injection agents for the treatment of impaired detrusor contractility. We have investigated the ability of the MDC to deliver a persistent expression of marker gene (␤-galactosidase) in the bladder wall and to potentially improve the contractility of the bladder following injury. Although only a ␤-galactosidase reporter gene is used, this study paves the way for future studies involving skeletal muscle-derived cells that are genetically engineered to persistently express therapeutic genes such as growth factors (ie nerve growth factor, vascular endothelial growth factor, insulin growth factor) to improve the healing of deficient urinary tissues. Figure 1 ) ␣-Smooth muscle actin (␣-SMA) is a known marker for the smooth muscle cell phenotype and is expressed in bladder detrusor muscle. 30 ␣-SMA also represents a marker for myofibroblasts. 31 Immunohistochemical (A-F) and RT-PCR (G) analysis in Figure 1 confirmed that ␣-SMA is expressed in the early preplate culture (pp1, pp2) (a, g) and in control smooth muscle cells isolated from bladder (b), but not in the highly purified pp6 myogenic cells (c, d, g) or mc13 (e, f, g) cells. Finally, we have observed that stimulation of mc13 with TGF-␤1 for 24 and 48 h will induce the expression of ␣-SMA in contrast to that observed in the non-stimulated mc13, suggesting that the muscle-derived stem cells can be induced to express ␣-SMA in vitro (h). (Figure 2 ) Transplantation of the primary MDC into the lower urinary tract is feasible (Figure 2) , as demonstrated by the large number of mononucleated pp6 and mc13 cells as well as the many myotubes and myofibers expressing the LacZ reporter gene at 1 (a, b), 2 (c, d), 4 (e, f) and 8 (g, h) weeks after injection. We have observed that ␤-galactosidase-expressing myotubes and myofibers within the bladder injected with pp6 and mc13 persist for up to 6 months after implantation (not illustrated).
Results

Phenotypic characterization of MDC and mc13 cells in vitro (
MDC-mediated ex vivo gene transfer of a marker gene in the bladder
By using the ␤-galactosidase assay (ONPG), we compared the level of ␤-galactosidase expression mediated by injection of transduced pp6 at each time interval for up to 70 days after injection. After pp6 injection, the level of the transgene expression did gradually decrease. In fact, 88%, 79% and 60% of the transgene expression observed at 5 days (675 ng of ␤-galactosidase) remained at 15, 35 and 70 days after injection, respectively (data not shown). These results correlate with the LacZ staining showing that a decrease of transgene expression is found in the injected bladder from 1 week to 8 weeks after implantation of pp6 cells (Figure 2a , c, e, g). In contrast, based on LacZ staining, the use of a clonal population of muscle-derived stem cells leads to a persistent transgene expression in the injected bladder at the same time-points after injection (Figure 2b , d, f, h).
The muscle-derived cells differentiated into myotubes and myofibers within the injected bladder wall (Figure 3)
We have observed that the area in the injected bladder that was LacZ-positive (a, c, e, g, i, k) was also found to express fast myosin heavy chain (MyHCs) at 1 (b, d), 4 (f, h) and 8 weeks after injection (j, l) with both pp6 (a, b, e, f, i, j) and mc13 (c, d, g, h, k, l). These results suggest that the injected muscle-derived cells (pp6 and mc13) are capable of differentiating into myotubes and myofibers within the injected bladder wall.
Physiological improvement of the bladder contractility by using muscle-based tissue engineering (Figure 4)
A schematic diagram of the bladder injury and location of the bladder strip is presented in Figure 4a . The first set of experiments was performed in mature, female rats. Contractile responses were measured from three groups of bladders: (1) sham-operated and saline-injected (control); (2) cryoinjured + saline-injected (Cryo + saline); and (3) cryoinjured + pp6 injected (Cryo + pp6). Groups 2 and 3 were also repeated where saline and pp6 were injected at 1 week after injury. Contractions were evoked by electrical stimulation at 20 Hz using a train of 80 shocks. The contractile curve of the intact bladder strips reached its plateau in approximately 2 s and remained there an additional 4 s after the stimulation ended (b). The amplitude of the contractile curve of the injured bladder was lower than that of the intact bladder (c).
Improvement of detrusor contractility following pp6 injection was dependent on the time of injection. Contraction amplitudes of bladder strips taken 2 weeks after cryo + immediate saline injection and cryo + immediate pp6 injection were similar, but both were significantly lower than the control bladder strip ( * P Ͻ 0.05) (d). In contrast,
Figure 1 Phenotypic characterization of muscle derived cells for ␣-SMA in vitro. The pp6 (c, d) and mc13 cells (e, f) in culture did not express ␣-SMA in contrast to that observed in pp1/pp2 (a) and bladder-derived smooth muscle cell (b) populations. Panels (d) and (f) are phase contrasts of panels (c) and (e), respectively. By RT-PCR, we further confirmed that the early preplate (pp1/pp2) culture was positive for ␣-SMA, while both the pp6 and the mc13 were found negative for ␣-SMA (g). The stimulation of mc13 with 5 ng/ml TGF-␤1 for 24 and 48 h induced the expression of ␣-SMA in contrast to that observed in the non-stimulated mc13 (h). Magnification a-f, ×200.
bladders that were injected with pp6 1 week after the cryoinjury showed significantly improved bladder contractility compared with bladders injected with saline 1 week after cryoinjury (+P Ͻ 0.05) (e).
We have repeated this set of experiments by injecting the clonal population of MDC (mc13) and a non-purified population of myogenic cells (pp1/pp2) into adult SCID mice. The cells were injected into the bladder at 1 week after cryoinjury. The results were still compared with the control (sham-operated and saline-injected) and the cryoinjured bladder injected with saline (f). The bladder contractions of the cryoinjured bladders injected with saline (cryo + saline) were significantly lower than those of the control bladders ( * P Ͻ 0.05) indicating that the injury negatively affected the contractile machinery and/or the postganglionic nerve terminals. The cryoinjured bladders injected with mc13 significantly improved bladder contractility (+P Ͻ 0.05) in contrast to that observed with pp1-pp2 (f). These results further validate that the use of highly purified MDC, including stem cells (mc13), can improve the bladder contractility post-injury in a more effective manner than the use of non-purified MDC (pp1-pp2).
The muscle-derived cells differentiated into ␣-SMAexpressing cells in the bladder (Figure 5)
After ␣-SMA-negative MDC (pp6, mc13) were injected into the bladder wall, we colocalized LacZ-positive cells with ␣-SMA-positive cells within the injected bladder site at 2 and 8 weeks after injection ( Figure 5 ). At 8 weeks
Gene Therapy after transplantation of pp6 (a, c, e) and 2 weeks after transplantation of mc13 (b, d, f), the injected area contained many ␤-galactosidase-expressing cells which were also positive for ␣-SMA suggesting that the MDC differentiated into smooth muscle cells in vivo (arrows e, f). However, within the same injected area, we have also detected ␤-galactosidase-expressing cells that were not colocalized with ␣-SMA-positive cells (arrowheads e, f) showing that not all of the injected cells differentiated into smooth muscle lineage.
The muscle-derived cells differentiated into myotubes and myofibers with neuromuscular junctions (Figure 6)
Acetylcholine receptors (AChRs) are localized at the endplate of neuromuscular junctions. 16, 32 An AChR staining was performed to identify the location of neuromuscular junctions in skeletal myofibers as a means of determining whether the ␤-galactosidase-expressing myofibers found in the injected bladders were innervated ( Figure 6 ). The presence of myofibers within the bladder injected with pp6 and mc13 was determined by the detection of MyHCs (a, c). We found that, at 15 days after injection, the AChRs became clustered at the plasma membrane of the myofibers (b, d, arrows) showing the accumulation of AChRs at the endplate location of the neuromuscular junction. However, several myofibers expressed AChRs in a diffused manner throughout the membrane and probably were not innervated at this time-point (stars, d). These results imply that the myofibers that become innervated rapidly may contribute to the improvement in bladder contractility.
Discussion
A major advance in the treatment of urinary incontinence over the last 10 years has been the technique of using injectable bulking agents. These bulking agents have several advantages over conventional surgical repair of incontinence. It is a quick, pain-free procedure with minimal sedation and post-operative risks allowing the patient to resume full activity immediately. The most common and successful bulking agent, gluteraldehyde cross-linked bovine collagen, is manufactured in the form of an injectable paste. [33] [34] [35] Although 80% of patients report a decrease in leakage of urine within the first 3 months after collagen injection, the long-term outcome has been disappointing due to some major disadvantages. 36 First, collagen is often reabsorbed. This adversely affects the successful outcome and requires repeat injections (average of between two and three), which become expensive for the patient. Lastly, 3-4% of patients are allergic to the cow source of collagen and are excluded from this type of therapy.
To circumvent the problems of collagen injection, we explored the use of MDC (pp6 and mc13) to improve urinary incontinence. There are several potential advantages of MDC injection over bovine collagen injection. First, an autologous injection of MDC will prevent immune responses and should persist significantly longer than other injectable agents. Indeed, we have recently demonstrated significantly improved survival of MDC over bovine collagen after 30 days after injection. 37 Secondly, a muscle biopsy from a patient can easily be performed in an office setting. From this muscle biopsy, MDC can be rapidly isolated and grown in vitro to obtain large quantities of cells in a relatively short period of time. Lastly, MDC injection into the urinary tract can function as more than just a simple bulking agent. The cultured MDC can be used in two ways: (1) as a suspension for direct injection into the bladder wall to serve as an alternative bulking agent; and/or (2) for ex vivo gene therapy, where the autologous cells are used to deliver specific growth factors or cytokines, as well as to differentiate into the smooth muscle lineage to improve smooth muscle repair. Our results demonstrated that some of the injected MDC (pp6 and mc13) appear to have differentiated into the smooth muscle lineage, while some of them differentiated into myotubes and myofibers that became innervated and consequently improved the contractility of the injured bladders. Although the presence of clusters of acetylcholine receptors in the ␤-galactosidase-expressing myofibers in the injected bladders is an indirect way to demonstrate innervation, the presence of cholinergic receptor accumulation, as well as high cholinesterase activity in small segments of the plasma membrane of myofibers, has been previously interpreted as the location of neuromuscular junctions. 16, 32 The ability of the injected cells to differentiate into both innervated myofibers and smooth muscle lineage contributed to the improvement of bladder contractility observed in this study, but only when the MDC (pp6) were injected at 1 week after injury in contrast to results observed when the cells were injected immediately after the injury. Although the reasons for this are still unclear, we hypothesize that an immediate inflammatory response caused by the cryoinjury may limit the success of an immediate MDC injection. Finally, an improvement of contractility in the injured bladders was also observed with non-purified muscle-derived cells (pp1/pp2), but in a less effective manner than observed with highly purified MDC. These results suggest that the low number of desmin-positive cells found in non-purified muscle-derived cell populations (pp1/pp2), which have a limited capacity to fuse into myotubes, hinders their ability to significantly improve the bladder contractility after injury. It is important to note that the force produced by bladder strips in Figure 4f cannot be directly compared with the force produced by the bladder strips in Figure 4d and e, because they were taken from mice and rats, respectively. We hypothesize that there is a much greater difference in contractile strength between the injured, non-treated mice and the control mice than there is between the injured, non-treated rats and the control rats, because the mouse bladder is smaller than the rat bladder and therefore the cryoprobe created a greater injury.
In our laboratory, as well as in others, much research is being done on the characterization and isolation of pluripotent stem cells derived from skeletal muscle. Furthermore, recent studies have reported that these cells may exist in skeletal muscle. 7, 9, [23] [24] [25] [26] [27] [28] [29] The presence of stem cells in skeletal muscle makes this tissue an attractive source of cells that are capable of enhancing the healing of various tissues. 9 In fact, we have recently observed that the genetic engineering of MDC (mc13) to express rhBMP-2 can be used to enhance closure of a non-healing skull defect. 9 These results strongly imply that this purified population of MDC is superior to other populations of muscle-derived cells, not only in terms of survival but also in the ability to differentiate into multiple lineages. We therefore investigated whether these MDC (pp6 and mc13) could differentiate into the smooth muscle lineage.
Our data showed that both pp6 and mc13 are negative for ␣-SMA in vitro, but become positive for ␣-SMA after their injection within the bladder in vivo, suggesting their differentiation into smooth muscle cells at the injected site. The ␣-SMA isoform is a useful marker of early visceral and vascular smooth muscle differentiation. 30, 31 Some positive ␣-SMA staining was detected within the LacZ-transduced myotubes and myofibers in the bladder wall at 2 and 8 weeks after injection. These results imply that some of the MDC still fused to form myotubes and myofibers that expressed, at least in part, markers of smooth muscle cells. We acknowledge that using the ␣-SMA marker to identify cells' differentiation to smooth muscle cells does not provide concrete evidence that this phenomenon is actually occurring. Since it has been observed that ␣-SMA is transiently expressed in immature myofibers, we cannot exclude the possibility that myotubes and myofibers expressing ␣-SMA found within the injected bladders are related to the activation of the ␣-SMA promoter in immature myofibers. 38 However, the lack of ␣-SMA in many myotubes and myofibers found in the bladders injected with MDC showed that the promoter is not activated in all immature muscle cells and therefore suggests that another mechanism is involved for the expression of ␣-SMA in MDC following implantation in the bladder. The fusion of MDC with smooth muscle cells may also explain this observation. Indeed, it has already been reported that dermal fibroblasts can fuse with myogenic cells. 39 Furthermore, we cannot exclude from these results that some of the ␤-galactosidase-expressing myotubes and myofibers within the injected bladder may undergo a trans-differentiation event toward smooth muscle lineage and therefore, the expression of ␣-SMA is a step forward in that process. Indeed, we have recently observed that the transplantation of mc13 within skeletal muscle leads to the formation of many myofibers which, upon muscle injury, will eventually undergo a trans-differentiation process by which the myofibers become fibrotic. 40 To rule out the possibility that these injected MDC underwent a transdifferentiation process and became fibrotic cells (which would also express ␣-SMA), the injected bladder sections were also stained for vimentin and were found to be negative for expression of this fibrosis marker (data not shown). The mechanism by which the MDC acquired the expression of ␣-SMA following injection in the bladder is still unclear and requires further investigation. Therefore, this article only suggests that the cells may differentiate into smooth muscle upon injection into the bladder and consequently contribute to the improvement in contractility.
The goal of these experiments was to establish a foundation for potential future clinical applications of musclederived cell-based tissue engineering and ex vivo gene
Figure 4 Physiological improvement of the injured bladder via muscle-derived cell implantation. Schematic representation of the cryoinjury model and location of the bladder strips (a). A representative contractile curve of bladder strips evoked by electrical stimulation (20 Hz 80 shocks) of control (b) and 30-s cryoinjured (c) rat bladders. Cryoinjured rat bladders with immediate saline and pp6 injection both resulted in a significant ( * P Ͻ 0.05) decrease of contractile responses to electrical field stimulation when compared with the control bladder (d). However, the pp6 injected at 1 week after cryoinjury in the rat bladder displayed a significant improvement in bladder contractility versus cryo + saline (1 week) injection (+P Ͻ 0.05) for up to 80% of the normal baseline level, which was not significantly different from the control group (e). The cryoinjured mouse bladder injected with mc13 at 1 week after injury significantly improved bladder contractility (+P Ͻ 0.05) in contrast to that observed with pp1/pp2 (f). * Compared with control;
+ compared with cryo + saline. therapy for urological dysfunction. We were able to successfully isolate skeletal MDC and inject them into the bladder wall, which led to the formation of myotubes and myofibers in the smooth muscle layers of the lower urinary tract. We have demonstrated the feasibility of MDCmediated gene transfer to the bladder and have observed a persistent transgene expression up to 8 weeks after injection. Although a decrease in transgene expression was observed with pp6 (60%) from 1 to 8 weeks, a stable transgene expression was observed with mc13 at all timepoints tested. These results suggest that the use of a clonal population of MDC will further improve gene transfer to the bladder when compared with a non-clonal population of MDC. Furthermore, pp6 cells were transduced with adenovirus, whereas mc13 cells were stably transfected with a plasmid encoding the ␤-galactosidase reporter gene. Adenovirus remains episomal within the transduced cells since it is not incorporated into the cells' genome. Therefore, the cells may have replicated over time losing the expression of the transgene. This discrep- ancy may have contributed to the differential persistence of the transgene observed in this study with mc13 and pp6 cells.
In addition to the numerous muscle cells, myotubes and myofibers that survived in the lower urinary tract up to 8 weeks after injection, many MDC persisted for over 6 months. To our knowledge, this is the longest persistence of gene transfer in urological tissues ever demonstrated by tissue engineering. The transplantation of MDC in immunodeficient SCID mice allowed us to demonstrate the efficacy of this treatment in the absence of immunological problems. While an improvement of the bladder strength was observed at 2 weeks after injection in immune-competent rats injected with mouse-derived pp6 cells, we have not performed long-term studies. Recent studies from our research group have shown that a population of muscle-derived stem cells appears to exhibit immune privileged behavior that may lead to cell survival even in a xenotransplantation model. 41 However, it is clear to us that the use of the adenoviral vector as well as the bacterial ␤-galactosidase to follow the fate Gene Therapy of the injected cells will trigger an immune response in long-term experiments. 42 In summary, we have (1) demonstrated the feasibility and survival of MDC injection into the bladder wall; (2) established improved detrusor contractility with MDC injection in a bladder injury model; (3) revealed the maturity of the ␤-galactosidase expressing myofibers in the injured bladder by demonstrating the presence of neuromuscular junctions based on the accumulation of AChRs in small segments of their membrane; and (4) demonstrated the possiblity of MDC differentiating into a smooth muscle lineage when injected into the bladder wall. We hypothesize that autologous MDC injections (muscle cells harvested from and cultured for a specific incontinence patient) can be used as a nonallergenic agent to improve bladder contractility. We are aware that detrusor weakness is a slowly progressing problem in humans and that our experiments have only shown physiological improvement following an acute injury. Therefore, the graft success and the physiological improvement observed in these experiments may be
Figure 6 The muscle-derived cells differentiated into myotubes and myofibers with neuromuscular junctions in the injected bladders. Myotubes and myofibers expressing fast myosin heavy chain (a, c) were also found to express AChR clustered in their membranes at 15 days after injection with pp6 (b) and mc13 (d) suggesting that the myofibers became innervated (arrows). However, it has also been observed that in many myotubes and myofibers, the AChR expression was diffused throughout the myofibers, which is suggestive of the lack of innervation of these myofibers (stars, d). Magnification a-d, ×400.
absent in chronic weakness usually associated with humans. We will further investigate in subsequent experiments the ability of MDC to bulk up the urethral wall, enhance coaptation and improve the urinary sphincter muscle. This technology for muscle-based gene therapy and tissue engineering may be superior to existing treatments for urinary incontinence based on injectable agents.
Materials and methods
Animals
All experiments were performed on mature SCID (severe combined immunodeficient) mice and mature female Sprague-Dawley rats in accordance with the requirements and recommendations in the Guide for the Care and the Use of Laboratory Animals (US Public Health Service, NIH Publication No. 1985) . This project was approved by the Animal Research and Care Committee at Children's Hospital of Pittsburgh and the University of Pittsburgh (protocol 14-98). Only certified virus-free animals were used. The animals were housed in an approved viral gene therapy facility (Rangos Research Center, Children's Hospital of Pittsburgh).
Purification of primary muscle-derived cells
Muscle mass from neonatal normal mice (C57BL/6J) was removed and minced into a coarse slurry. Cells were enzymatically dissociated by the addition of collagenasetype XI 0.2% for 1 h at 37°C, dispase (grade II 240 unit) for 30 min, and trypsin 0.1% for 30 min. The muscle cell extract was preplated on collagen-coated flasks, and the myogenic population in each flask was evaluated by desmin staining. Previous experiments have shown that early preplates (pp1-2) contain a majority of fibroblasts (5-15% desmin-positive) and the late preplates (pp5-6) are enriched with desmin-positive cells (>80%). [20] [21] [22] 41 The cells used in this experiment were taken from the late preplate (pp6) and were shown to express myogenic and stem cell markers. 9 The proliferation medium used to grow the cells was Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10% horse serum (HS) and 1% penicillin/streptomycin. All the culture medium supplies were purchased through Gibco Laboratories (Grand Island, NY, USA).
Isolation of a clonal population of purified musclederived cells (mc13)
Primary muscle cells were isolated from mdx mice (C57BL/10ScSn mdx/mdx) and purified as described above. Pp6 cells from the mdx muscle were transfected with 10 g of a linear plasmid encoding for the ␤-galactosidase, minidystrophin and neomycin resistance genes using the lipofectamine reagent (GIBCO BRL) according to the manufacturer's instructions. 43 At 72 h after transfection, cells were selected with 3 mg/ml of G418 (Gibco BRL) for 10 days until colonies appeared. Colonies were tested for expression of LacZ and dystrophin genes. One of these clones, mc13, was used for these experiments. 9 The mc13 cells stimulated in vitro with TGF-␤1 were grown in serum free DMEM + 5 ng/ml TGF-␤1 for 24 and 48 h.
RT-PCR for ␣-SMA
RT-PCR analysis: pp1/pp2, pp6, and mc13 cells were isolated as previously described. The cells' total RNA was extracted using a monophasic solution of phenol and guanidine isothiocyanate (TRIzol, 10 cm 2 /ml, Gibco BRL). For the PCR analysis of RNA, cDNA was prepared by reverse transcription (RT) of 1 g of each RNA sample in a 20 l reaction volume containing 50 ng of random hexamers, 1 l of 50 mM of MgCl 2 , 1 l of 10 mM of dNTP, 2 l of 0.01 M of DTT and 2 l of 10 × PCR buffer. For the last step, 200 units of Superscript II were added; a control that was free of Superscript II was also used. Next, the cDNA from the RT went through the PCR reaction. The PCR amplification was performed in a 50 l reaction volume containing 2 l of cDNA, 1.5 l of 50 mM MgCl 2, 1 l of 10 mM dNTP, 1 l of 10 mM primer, 0.5 l of Taq DNA polymerase and 5 l of 10 × PCR buffer. The sequences for the PCR primers were designed as follows: ␤-actin sense-GTGGGCCGCTCTAGGCAC-CAA, antisense-CTCTTTGATGTCACGCACGATTTC; ␣-SMA sense-CTGGAGAAGAGCTACGAACTGC, antisense-CTGATCCACATCTGCTGGAAGG. The PCR cycle was 94°C for 3 min, 32 cycles of 94°C for 30 s, 56°C for 30 s, 72°C for 30 s, and 72°C for 7 min. The PCR products were separated by size in a 2% agarose gel and directly read and recorded by camera.
Genetic engineering of muscle-derived cells (pp6) via adenoviral vector
We used a previously described E1-E3-deleted recombinant adenovirus that contains the ␤-galactosidase gene under the control of the human cytomegalovirus (HCMV) promoter followed by the SV40 t-intron and polyadenylation signal. Plates were incubated for 3 h at 37°C at a multiplicity of infection equal to 50 (MOI = 50) to allow for an adequate infection. Plates were placed at 37°C overnight.
MDC injection, tissue harvest and histology
A low midline incision was made to expose the bladder. Using a Hamilton syringe, 1.5 × 10 6 cells suspended in 20 l of HBSS were injected bilaterally into the bladder wall of each SCID mouse. The animals were killed at 1 (5 days), 2 (15 days), 4 (35 days), and 8+ (70 and 180 days) weeks following injection with pp6, whereas the animals injected with mc13 were killed at 1, 2, 4 and 8 weeks after injection. The bladders were removed and snapped frozen using 2-methylbutane pre-cooled in liquid nitrogen. The tissues were cryostat sectioned (10 m) and analyzed by hematoxylin and eosin, LacZ, and immunofluorescent staining. Serial 10 m sections of the injected tissue were stained for LacZ expression as follows. The tissues were first fixed with 1.5% glutaraldehyde (Sigma) for 1 min and rinsed twice in phosphate-buffered saline (PBS). They were then incubated in X-gal substrate [0.4 mg/ml 5-bromo-chloro-3-indolyl-␤-D-galactoside (Boehringer-Mannheim, Indianapolis, IN, USA), 1 mM MgCl 2 , 5 mM K 4 Fe(CN) 6 /5 mM K 3 Fe(CN) 6 in PBS] 3 h overnight at 37°C. The ONPG assay was also performed, using a protocol previously described, in order to quantitate the transgene expression level in the injected bladder tissues. 44 Immunohistochemical staining for fast myosin heavy chain Tissue sections were fixed with cold acetone (Ϫ20°C) for 1 min and blocked with 5% horse serum for 1 h. Following rinses in PBS, the tissues were incubated overnight with the primary antibody (mouse monoclonal anti skeletal myosin (fast) clone My32, 1:400; Sigma Chemical, St Louis, MO, USA). After three rinses in PBS, the secondary antibody, Cy3 conjugated anti-mouse IgG (1:200; Sigma Chemical) was added for 1 h.
Immunohistochemical staining for acetylcholine receptors (AChRs)
The tissues were fixed with cold acetone for 1 min and blocked with 5% horse serum for 3 h. The sections were incubated overnight at room temperature in a humid chamber with primary antibodies (1:100 monoclonal mouse anti-acetylcholine receptors; MAB398; Chemicon, Temecula, CA, USA) in PBS, pH 7.4. After three rinses in PBS, the sections were incubated with a second antibody, biotin conjugated goat anti-mouse (1:200; Sigma Chemical), for 1 h. After three rinses in PBS, the sections were incubated with streptavidin conjugated to Cy3 immunofluorescence for 1 h (1:200; Sigma Chemical).
Immunohistochemistry for ␣-smooth muscle actin (␣-SMA)
The cells (in vitro) and injected tissues (in vivo) were fixed with cold methanol (in vitro) or acetone (in vivo) for 2 min and blocked with 5% horse serum for 1 h. The cells (in vitro) or tissue sections (in vivo) were incubated overnight at room temperature in a humid chamber with primary antibodies (1:1000 in vitro, or 1:400 in vivo monoclonal mouse anti-␣ smooth muscle actin; F-3777; Sigma Chemical) in PBS. After three rinses in PBS, the cells or sections were incubated with a second antibody, antimouse conjugated to Cy3 immunofluorescence for 1 h (1:200; Sigma Chemical).
The ␣-SMA expressing cells were colocalized with cells expressing ␤-galactosidase to further substantiate the Gene Therapy injected cells' ability to differentiate into a smooth muscle lineage. The colocalization of ␤-galactosidase and the ␣-SMA was performed using the following protocol. The muscle sections were first fixed with cold acetone (100%) followed by a 1 h blocking step with horse serum (10%) and the ␣-SMA was detected by immunohistochemistry as described above. The sections were subsequently incubated with a biotinylated anti-␤-galactosidase antibody (1:100 in PBS; Sigma) followed by streptavidin conjugated to fluorescein (1:300 in PBS, Sigma), to stain the ␤-galactosidase-expressing cells.
Physiological testing and contractility studies
The first part of the experiments was performed on mature, female Sprague-Dawley rats (250-300 g) (Hilltop Laboratories, Pittsburgh, PA, USA), a larger animal model, to test the feasibility of the experiment, as well as the most appropriate time for cell injection. The second part of the contractility experiments was performed on mature SCID mice. The animals were anaesthetized with halothane. After surgical preparation, a low midline incision was made to expose the bladder. Tissue damage was invoked by placing a cryoprobe (aluminum rod chilled on dry ice) against the bladder wall for 30 s. MDC were injected directly into the injured site in the bladder wall. Two experimental groups were established to test several variables.
The first experiment (pp6 cells injected in SpragueDawley rats) was divided into three groups: (1) shamoperated and saline-injected (control); (2) cryoinjured and saline-injected (cryo + saline); or (3) cryoinjured and pp6-injected (cryo + pp6). For groups 2 and 3, saline or pp6 were either injected immediately or at 1 week following the cryoinjury. At 2 weeks following the injections, the rats were killed and bladder strips taken directly from the injury/injection site were prepared to measure contractile response. The preparations were mounted in 5 ml organ baths containing Krebs solution (mmol/l: NaCl, 113; KCl, 4.7; CaCl 2 , 1.25; MgSO 4 , 1.2; NaHCO 3 , 25; KH 2 PO 4 , 1.2; glucose, 11.5) and constantly bubbled with a mixture of 95% O 2 and 5% CO 2 . The initial tension was set to 10 mN and isometric contractions were measured with strain-gauge transducers (Grass F3, Astro-Med, West Warwick, RI, USA) coupled with a TBM4 strain gauge amplifier (World Precision Instruments, Sarasota, FL, USA) and recorded on a computer-based data acquisition program (Windaq, DATAQ Instruments, Akron, OH, USA). The amplitude of the contractile response was monitored and computed by a calculation program (WindaqEx, DATAQ). After 20 min equilibration, electrical field stimuli were applied through two platinum wire electrodes positioned on the top and the bottom of the organ bath, 4 cm apart. The bladder strips were stimulated with square wave pulses of 0.25 ms duration with maximal voltage (100 V) and frequency response curves constructed using 80 shocks at 20 Hz.
A few variables were changed for the second part of the experiment (mc13 cells injected into SCID mice). One week after the cryoinjury, mc13 cells were injected into the injured site of the bladder wall, similar to group 3. Because we obtained poor contractility results for the group that was injected with pp6 cells immediately after the cryoinjury (Figure 4 ), mc13 cells were only injected into the injured bladder at 1 week after injury. To test whether non-purified muscle cells could lead to an improvement in contractile strength, we have also injected pp1/pp2 cells (a population of muscle-derived cells that contain a majority of fibroblasts, ie 5-15% desmin-positive cells) into the injury site. The physiological assessment of the injured bladder after injection was determined as previously described for pp6 injected into the rat bladder. Statistics were done by ANOVA.
